# An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

> **NCT06326476** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 12 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Siplizumab

## Key facts

- **NCT ID:** NCT06326476
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06326476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06326476, "An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06326476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*